EP1663339A1 - Endoluminal prosthesis comprising a therapeutic agent - Google Patents
Endoluminal prosthesis comprising a therapeutic agentInfo
- Publication number
- EP1663339A1 EP1663339A1 EP04766458A EP04766458A EP1663339A1 EP 1663339 A1 EP1663339 A1 EP 1663339A1 EP 04766458 A EP04766458 A EP 04766458A EP 04766458 A EP04766458 A EP 04766458A EP 1663339 A1 EP1663339 A1 EP 1663339A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- melatonin
- stent
- prosthesis
- drug
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2493—Transmyocardial revascularisation [TMR] devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Definitions
- Endoluminal prosthesis comprising a therapeutic agent
- a therapeutic agent locally, in particular from an intraluminal prosthesis such as a coronary stent, directly from the surface of the prosthesis or from pores, micropores, perforationsor pits in the prosthesis body, directly bounded on the prosthesis or mixed or bound to a polymer coating applied on the prosthesis, or mixed or bound to a glue applied to the prosthesis, to modulate the healing response after vascular injury, to improve endothelial cell regrowth, and to inhibit inflammation induced by the injury caused by the implantation of the intraluminal prosthesis and inhibiting tissue proliferation and thereby preventing stenosis of the prosthesis.
- an intraluminal prosthesis such as a coronary stent
- Re-narrowing (restenosis) of an atherosclerotic coronary artery after percutaneous transluminal coronary angioplasty occurs in 10-50% of patients undergoing this procedure and subsequently requires either further angioplasty or coronary artery bypass graft. While the exact hormonal and cellular processes promoting restenosis are still being determined, the present understanding is that the process of PTCA, besides opening the atherosclerotically obstructed artery, also injures resident coronary arterial smooth muscle cells (SMC).
- SMC coronary arterial smooth muscle cells
- adhering platelets, infiltrating macrophages, leukocytes, or the smooth muscle cells (SMC) themselves release cell derived growth factors with subsequent proliferation and migration of medial SMC through the internal elastic lamina to the area of the vessel intima.
- Further proliferation and hyperplasia of intimal SMC and, most significantly, production of large amounts of extracellular matrix over a period of 3-6 months results in the filling in and narrowing of the vascular space sufficient to significantly obstruct coronary blood flow.
- Heparin is the best known and characterised agent causing inhibition of SMC proliferation both in vitro and in animal models of balloon angioplasty-mediated injury.
- the mechanism of SMC inhibition with heparin is still not known but may be due to any or all of the following: 1) reduced expression of the growth regulatory protooncogenes c-fos and c-myc, 2) reduced cellular production of tissue plasminogen activator, or 3) binding and dequestration of growth regulatory factors such as fibrovalent growth factor (FGF).
- FGF fibrovalent growth factor
- angiopeptin a somatostatin analog
- calcium channel blockers angiotensin converting enzyme inhibitors
- angiotensin converting enzyme inhibitors captopril, cilazapril
- cyclosporin A trapidil
- trapidil an antianginal, antiplatelet agent
- terbinafine antifungal
- colchicine and taxol antitubulin antiproliferatives
- PDGF SMC mitogen platelet derived growth factor
- PTCA percutaneous transluminal coronary angioplasty
- CABG coronary artery bypass graft
- a major difficulty with PTCA is the problem of post-angioplasty closure of the vessel, both immediately after PTCA (acute reocclusion) and in the long term (restenosis).
- the mechanism of acute reocclusion appears to involve several factors and may result from vascular recoil with resultant closure of the artery and/or deposition of blood platelets along the damaged length of the newly opened blood vessel followed by formation of a fibrin/red blood cell thrombus.
- intravascular stents have been examined as a means of preventing acute reclosure after PTCA.
- Extracellular matrix surrounds SMC and is rich in heparin-like glycosylaminoglycans which are believed to be responsible for maintaining SMC in the contractile phenotypic state.
- PDGF platelet derived growth factor
- bFGF basic fibroblast growth factor
- EGF epidermal growth factor
- PDGF platelet derived growth factor
- bFGF basic fibroblast growth factor
- EGF epidermal growth factor
- PDGF platelets adhering to the damaged arterial luminal surface, invading macrophages and/or leukocytes, or directly from SMC (i.e., BFGF) provoke a proliferation and migratory response in medial SMC.
- a therapeutic agent is delivered to the site of arterial injury.
- the conventional approach has been to incorporate the therapeutic agent into a polymer material which is then coated on the stent.
- the ideal coating material must be able to adhere strongly to the metal stent both before and after expansion, be capable of retaining the drug at a sufficient load level to obtain the required dose, be able to release the drug in a controlled way over a period of several weeks, and be as thin as possible so as to minimize the increase in profile.
- the coating material should not contribute to any adverse response by the body and should be perfectly biocompatible (i.e., should be non-thrombogenic, non-inflammatory, etc.).
- An alternative to this polymer/drug loading method is direct binding of the therapeutic agent to the metal surface.
- This method has the advantage to be perfectly biocompatible. Disadvantages are however the limited dose of drug that can be loaded on the stent and the (too) fast release of the drug.
- An other alternative is to use a drug impregnated biocompatible glue, in particular a biocompatible oil/solvent emulsion. Also with this method the drug release is quite fast, but combination with a barrier coating could improve the release characteristics.
- Another approach is to design a stent that contains reservoirs which could be loaded with the drug. A coating or membrane of biocompatible material could be applied over the reservoirs which would control the diffusion of the drug from the reservoirs to the arterial wall. The advantages of this system is that much more drug can be loaded and much longer drug release can be achieved.
- Pharmacologic attemps to prevent restenosis Pharmacological attempts to prevent restenosis by pharmacologic means have thus far been unsuccessful and all involve systemic administration of the trial agents. Neither aspirin-dipyridamole, ticlopidine, acute heparin administration, chronic warfarin (6 months) nor methylprednisolone have been effective in preventing restenosis although platelet inhibitors have been effective in preventing acute reocclusion after angioplasty. The calcium antagonists have also been unsuccessful in preventing restenosis, although they are still under study. Other agents currently under study include thromboxane inhibitors, prostacyclin mimetics, platelet membrane receptor blockers, thrombin inhibitors and angiotensin converting enzyme inhibitors.
- antiproliferative (or anti-restenosis) concentrations may exceed the known toxic concentrations of these agents so that levels sufficient to produce smooth muscle inhibition may not be reached (Lang et al., 42 Ann. Rev. Med., 127-132 (1991); Popma et al., 84 Circulation, 1426-1436 (1991)).
- Stents which when expanded within the lumen of an angioplastied coronary artery, provide structural support to the arterial wall, are helpful in maintaining an open path for blood flow.
- stents were shown to increase angiographic success after PTCA, increased the stenosed blood vessel lumen and reduced the lesion recurrence at 6 months (Serruys et al., 331 New Eng Jour. Med, 495, (1994); Fischman et al., 331 New Eng Jour. Med, 496-501 (1994).
- heparin coated stents appear to possess the same benefit of reduction in stenosis diameter at follow-up as was observed with non-heparin coated stents.
- heparin coating appears to have the added benefit of producing a reduction in sub-acute thrombosis after stent implantation (Serruys et al., 93 Circulation, 412-422, (1996).
- sustained mechanical expansion of a stenosed coronary artery has been shown to provide some measure of restenosis prevention
- coating of stents with heparin has demonstrated both the feasibility and the clinical usefulness of delivering drugs to local, injured tissue off the surface of the stent.
- Numerous agents are being actively studied as antiproliferative agents for use in restenosis and have shown some activity in experimental animal models.
- rapamycin which is a toxic drug that affects not only SMC proliferation, but also endothelial cell regrowth and restoration and fibroblast proliferation after stent implantation, and the use of a polymer which always leads to the concern of an inflammatory reaction induced by the polymer, and potentially occurrence of late restenosis.
- Melatonin to coat the endoluminal prosthesis instead of and/or in addition to melatonin, use could also be made of a drug derived from melatonin, i.e. a drug which has a similar chemical structure, and which has analogous effects, in particular substantially the same effects, on the healing response of the blood vessel wall.
- a drug derived from melatonin i.e. a drug which has a similar chemical structure, and which has analogous effects, in particular substantially the same effects, on the healing response of the blood vessel wall.
- melatonin has a mode of action which is different from that of rapamycin.
- Melatonin has been shown to possess anti-inflammatory effects, among a number of other actions.
- Melatonin reduces tissue destruction during inflammatory reactions by a number of means.
- Melatonin by virtue of its ability to directly scavenge toxic free radicals, reduces macromolecular damage in all organs.
- melatonin The free radicals and reactive oxygen and nitrogen species known to be scavaged by melatonin include highly toxic hydroxyl radicals (-OH), peroxynitrite anion (ONOO-), and hypochlorous acid (HOCL), among others. These agents all contribute to the inflammatory response and associated tissue destruction. Additionally, melatonin has other means to lower the damage resulting from inflammation. Melatonin prevents the translocation of nuclear factor-kappa B (NF-kappaB) to the nucleus and its binding to DNA, thereby reducing the upregulation of a variety of proinflammatory cytokines, for example, interleukins and tumor necrosis factor alpha.
- NF-kappaB nuclear factor-kappa B
- melatonin inhibits the production of adhesion molecules that promote the sticking of leukocytes to endothelial cells.
- melatonin attenuates transendothelial cell migration and edema, which contribute to tissue damage.
- free radical scavengers and anti- inflammatory agents are considered not potent enough to block in-stent neointimal hyperplasia sufficiently, the present inventor has found a significant inhibition of peri-strut injury, peri-strut inflammation and neointimal hyperplasia in a pig stent coronary model.
- melatonin compared to sirolimus and especially paclitaxel is that melatonin does not block cells that are involved in the healing response. It only neutralise toxic compounds that lead to further cell damage, inflammation and an overstimulation of the smooth muscle cells resulting in neointimal hyperplasia and restenosis.
- Melatonin neutralises toxic compounds released by inflammatory cells in response to vascular injury. These compounds are tought to be responsible for an overstimulation of the healing response, leading to an abundant neointimal proliferation and restenosis. Melatonin has also no direct effect on the endothelial cell regrowth and indirectly, by eliminating toxic substances that also are toxic for endothelial cells, a positive effect on endothelial cell regrowth. Therefore there is no problem with potential late thrombotic occlusion of the stent by thrombus formation.
- melatonin is not cytotoxic for smooth muscle cells and other cells involved in the neointimal hyperplasia cascade, even at very high drug concentrations. Therefore, by using melatonin, toxic products that increase tissue damage and by doing so overstimulate the healing response resulting in an inappropriate smooth muscle cell proliferation, neointimal hyperplasia and finally resulting in stent narrowing are neutralised so that the stimulus for smooth muscle cell dedifferentiation and proliferation is eliminated before the neointimal hyperplasia cascade is stimulated. Different from other antioxidant drugs, melatonin has shown to have also direct effects on the inflammatory cells, inhibiting their activation during inflammatory processes after tissue injury.
- WO 98/30255 it may be advantageous according to WO 98/30255 to employ implanted devices, such as implanted stents capable of delivering the antioxidant substance for prolonged periods of time.
- implanted devices such as implanted stents capable of delivering the antioxidant substance for prolonged periods of time.
- Disadvantage of the use of a local drug delivery balloon is that the drug can only be released during a limited time period (up to 5 minutes) and that the efficacy of effective local drug delivery to the vascular wall is very low ( ⁇ 1 %-5%) and very variable.
- the antioxidant substance should be the preferred probutol since it is clear that the amount of the antioxidant substance which can be delivered with an implanted stent is much smaller than the amount that can be delivered with a catheter and that much larger amounts of the other antioxidant substances will be required to inhibit restenosis than of the more effective probucol.
- WO 98/30255 thus does not teach the combination of an implanted stent coated with melatonin so that this combination is novel with respect to WO 98/30255.
- the present invention is now based on the unexpected potent beneficial effect of local, stent mediated melatonin delivery on the vascular injury and inflammation, most probably due to the potent neutralizing effect of toxic free radicals, released during injury induced inflammation, by melatonin, combined with its direct anti-inflammatory effects, resulting in an improved healing, less smooth muscle cell stimulation and proliferation and less cellular ingrowth and narrowing of an endoluminal implant, endovascular prosthesis, shunt or catheter.
- the stent was air- dried using a warm laminar flow to evaporate the ethanol. Using this method a total melatonin load on the stent of 20 ⁇ g could be achieved. Implantation of these stents in a porcine coronary model with follow-up after 5 days revealed perfect biocompatibility of the system, without inducing any inflammation surrounding the struts of the stents on histological examination. After 4 weeks a 26% decrease in neointimal hyperplasia was surprisingly found compared to a bare stent. Similar experiments, using probucol, did not result in a significant effect on inflammatory response and neointimal hyperplasia.
- a dissatisity of the direct coating system is the fast release of the drug from the stent. In-vitro release curves showed a 90% release within 24 hours. In-vivo studies however showed sufficient melatonin coronary vascular concentration up to 15 days. In order to maintain significant melatonin concentrations for a longer period of time to obtain a durable anti-restenosis effect the present inventor has developed new methods to achieve a slower melatonin release.
- the drug was dissolved in a biocompatible emulsion of oil and a solvent wherein the drug is highly soluble.
- the stent was dipped in this emulsion several times and in between the different dipping steps air-dried using a warm laminar flow to evaporate the solvent and harden the drug/oil coating.
- Stent Implantation Domestic crossbred pigs of both sexes weighing 20-25kg were used. They were fed with a standard natural grain diet without lipid or cholesterol supplementation throughout the study. All animals were treated and cared for in accordance with the Belgium National Institute of Health Guidelines for care and use of laboratory animals.
- Grade 1 internal elastic membrane lacerated
- Mean score sum of score for each filament/ number of filament present.
- Morphometrv (Table) The neointimal hyperplasia of all groups was well organized. The lumen area of Melatonin stents was larger than the other groups. Furthermore the neointimal hyperplasia (0.89+0.28 mm2) and area stenosis (16 ⁇ 7%) of the Melatonin group were very limited, although the oversizing (balloon-area/IEL-area) was comparable among groups.
- N number of stents
- LA Lumen area
- IEL area inside the internal elastic lamina
- AS: Area stenosis ( 100 * (1 - LA I EL)
- Bal/IEL Balloon-area/IEL-area
- Indications Local delivery of melatonin by coating melatonin onto an endoluminal prosthesis, shunt or catheter and local delivery of melatonin to the surrounding tissue after implantation of the prosthesis, shunt or catheter, resulting in an inhibition of tissue injury, inflammation and cell proliferation to prevent neointimal hyperplasia and restenosis, prevention of tumor expansion and ingrowth into an endoluminal prosthesis and prevention of ingrowth of tissue into catheters and shunts inducing their failure.
- melatonin N-acetyl-5- methoxytrypta mine
- Direct drug coating on the metallic surface Stents are dipped in a solution of melatonin in a solvent, for example ethanol, at final concentration range 0.001 to 50 weight %. Solvent is allowed to evaporate to leave a film of melatonin on the stent.
- a solvent for example ethanol
- Polymers are biocompatible (i.e., not elicit any negative tissue reaction or promote mural thrombus formation) and degradable, such as lactone-based polyesters or copolyesters, e.g., polylactide, polycaprolacton- glycolide,polyorthoesters, polyanhydrides; poly-aminoacids; polysaccharides; polyphosphazenes; poly(ether-ester) copolymers, e.g., PEO-PLLA, or blends thereof.
- lactone-based polyesters or copolyesters e.g., polylactide, polycaprolacton- glycolide,polyorthoesters, polyanhydrides; poly-aminoacids; polysaccharides; polyphosphazenes; poly(ether-ester) copolymers, e.g., PEO-PLLA, or blends thereof.
- Nonabsorbable biocompatible polymers are also suitable candidates.
- Polymers such as polydimethylsiloxane; poly(ethylene-vingylacetate); acrylate based polymers or copolymers, e.g., poly(hydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone; fluorinated polymers such as polytetrafluoroethylene; cellulose esters.
- Polymer/drug mixture is applied to the surfaces of the stent by either dip-coating, or spray coating, or brush coating or dip/spin coating or combinations thereof, and the. solvent allowed to evaporate to leave a film with entrapped Melatonin.
- a stent whose body has been modified to contain micropores, pores, channels, perforations or pits is dipped into a solution of Melatonin, range 0.001 wt% to saturated, in organic solvent such as acetone or methylene chloride, for sufficient time to allow solution to permeate into the pores. (The dipping solution can also be pressurised to improve the loading efficiency.) After the solvent has been allowed to evaporate, the stent is dipped briefly in fresh solvent to remove excess surface bound drug. Additionally a solution of polymer, chosen from any identified in the first experimental method, can be applied to the stent as detailed above. This outer layer of polymer will than act as release and diffusion-controller for release of drug.
- Covalent Drug Tether Melatonin is modified to contain a hydrolytically or enzymatically labile covalent bond for attaching to the surface of the stent which itself has been chemically derivatized to allow covalent immobilization.
- Covalent bonds such as ester, amides or anhydrides may be suitable for this.
- Pericardial Delivery A Polymeric Sheet: melatonin is combined at concentration range previously highlighted, with a degradable polymer such as poly(caprolactone-glycolide) or non-degradable polymer, e.g., polydimethylsiloxane, and mixture cast as a thin sheet, thickness range 10p to 10 ⁇ m. The resulting sheet can be wrapped perivascularly on the target vessel. Preference would be for the absorbable polymer.
- Conformal coating Melatonin is combined with a polymer that has a melting temperature higher than 37°C, more particularly in the range of 40 to 45°C. Mixture is applied in a molten state to the external side of the target vessel.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04766458.6A EP1663339B1 (en) | 2003-08-14 | 2004-08-09 | Endoluminal prosthesis comprising a therapeutic agent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03447210 | 2003-08-14 | ||
EP04766458.6A EP1663339B1 (en) | 2003-08-14 | 2004-08-09 | Endoluminal prosthesis comprising a therapeutic agent |
PCT/EP2004/051755 WO2005016400A1 (en) | 2003-08-14 | 2004-08-09 | Endoluminal prosthesis comprising a therapeutic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1663339A1 true EP1663339A1 (en) | 2006-06-07 |
EP1663339B1 EP1663339B1 (en) | 2013-07-31 |
Family
ID=34178718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04766458.6A Not-in-force EP1663339B1 (en) | 2003-08-14 | 2004-08-09 | Endoluminal prosthesis comprising a therapeutic agent |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070005124A1 (en) |
EP (1) | EP1663339B1 (en) |
JP (1) | JP2007502135A (en) |
CN (1) | CN100400116C (en) |
CA (1) | CA2536961A1 (en) |
RU (1) | RU2360646C2 (en) |
WO (1) | WO2005016400A1 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60235775D1 (en) | 2001-11-08 | 2010-05-06 | Ziscoat N V | Intraluminal device with a therapeutic agent-containing coating |
US8263102B2 (en) | 2004-09-28 | 2012-09-11 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
WO2007011385A2 (en) | 2004-09-28 | 2007-01-25 | Atrium Medical Corporation | Heat cured gel and method of making |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US20060099235A1 (en) * | 2004-11-11 | 2006-05-11 | Medtronic Vascular, Inc. | Medical devices and compositions useful for treating or inhibiting restenosis |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
CA2626030A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
DE602007004124D1 (en) * | 2006-08-23 | 2010-02-11 | Blue Medical Devices B V | MEDICAL STENT WITH A COMBINATION OF MELATONIN AND PACLITAXEL |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
JP2010508897A (en) | 2006-11-06 | 2010-03-25 | アトリウム メディカル コーポレーション | Coated surgical mesh |
US9283305B2 (en) | 2009-07-09 | 2016-03-15 | Medtronic Vascular, Inc. | Hollow tubular drug eluting medical devices |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US8381774B2 (en) * | 2009-09-20 | 2013-02-26 | Medtronic Vascular, Inc. | Methods for loading a drug eluting medical device |
US8678046B2 (en) | 2009-09-20 | 2014-03-25 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
US8828474B2 (en) | 2009-09-20 | 2014-09-09 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
US20110070358A1 (en) | 2009-09-20 | 2011-03-24 | Medtronic Vascular, Inc. | Method of forming hollow tubular drug eluting medical devices |
US8887477B2 (en) * | 2009-11-16 | 2014-11-18 | Cordis Corporation | E beam sterilization of medical devices comprising bioactive coating |
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US8632846B2 (en) | 2010-09-17 | 2014-01-21 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
US8333801B2 (en) | 2010-09-17 | 2012-12-18 | Medtronic Vascular, Inc. | Method of Forming a Drug-Eluting Medical Device |
US8616040B2 (en) | 2010-09-17 | 2013-12-31 | Medtronic Vascular, Inc. | Method of forming a drug-eluting medical device |
CN103608006B (en) * | 2011-04-01 | 2017-07-07 | 伊亚索梅股份公司 | Combination comprising N acetyl group L cysteines and application thereof |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
WO2014151906A1 (en) | 2013-03-14 | 2014-09-25 | Medtronic Vascular Inc. | Method for manufacturing a stent and stent manufactured thereby |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US20220111244A1 (en) | 2013-09-04 | 2022-04-14 | Thomas Harrison Hunt | Neck exercise device and system |
CN104208059A (en) * | 2014-09-05 | 2014-12-17 | 中国医学科学院北京协和医院 | Application of melatonin in preparation of medicine for preventing smoking induced vascular damage |
WO2017127939A1 (en) | 2016-01-29 | 2017-08-03 | Neovasc Tiara Inc. | Prosthetic valve for avoiding obstruction of outflow |
EP3541462A4 (en) | 2016-11-21 | 2020-06-17 | Neovasc Tiara Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
CN108619581A (en) * | 2017-03-21 | 2018-10-09 | 微创心脉医疗科技(上海)有限公司 | The application of medication coat, interventional medical device and epiphysin in medication coat |
CA3073834A1 (en) | 2017-08-25 | 2019-02-28 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
CN113271890A (en) | 2018-11-08 | 2021-08-17 | 内奥瓦斯克迪亚拉公司 | Ventricular deployment of transcatheter mitral valve prosthesis |
CA3132873A1 (en) | 2019-03-08 | 2020-09-17 | Neovasc Tiara Inc. | Retrievable prosthesis delivery system |
CA3135753C (en) | 2019-04-01 | 2023-10-24 | Neovasc Tiara Inc. | Controllably deployable prosthetic valve |
CA3136334A1 (en) | 2019-04-10 | 2020-10-15 | Neovasc Tiara Inc. | Prosthetic valve with natural blood flow |
AU2020279750B2 (en) | 2019-05-20 | 2023-07-13 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
JP2022537559A (en) | 2019-06-20 | 2022-08-26 | ニオバスク ティアラ インコーポレイテッド | Thin artificial prosthetic mitral valve |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2071207T3 (en) * | 1990-02-08 | 1995-06-16 | Howmedica | INFLATABLE DILATOR. |
AU5959398A (en) * | 1997-01-09 | 1998-08-03 | Localmed, Inc. | Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US7208010B2 (en) * | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
AU3356000A (en) * | 1999-02-05 | 2000-08-25 | Nitrosystems, Inc. | L-arginine based formulations for treating diseases and methods of using same |
CA2395132A1 (en) * | 2000-01-05 | 2001-07-12 | Imarx Therapeutics, Inc. | Pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
ES2278952T3 (en) * | 2001-07-26 | 2007-08-16 | Avantec Vascular Corporation | DEVICES FOR MANAGING THERAPEUTIC AGENTS WITH VARIABLE LIBERATION PROFILE. |
-
2004
- 2004-08-09 CA CA002536961A patent/CA2536961A1/en not_active Abandoned
- 2004-08-09 US US10/595,104 patent/US20070005124A1/en not_active Abandoned
- 2004-08-09 EP EP04766458.6A patent/EP1663339B1/en not_active Not-in-force
- 2004-08-09 CN CNB2004800267318A patent/CN100400116C/en not_active Expired - Fee Related
- 2004-08-09 JP JP2006523013A patent/JP2007502135A/en active Pending
- 2004-08-09 WO PCT/EP2004/051755 patent/WO2005016400A1/en active Application Filing
- 2004-08-09 RU RU2006107816/14A patent/RU2360646C2/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO2005016400A1 * |
Also Published As
Publication number | Publication date |
---|---|
RU2006107816A (en) | 2007-09-20 |
CN100400116C (en) | 2008-07-09 |
JP2007502135A (en) | 2007-02-08 |
CA2536961A1 (en) | 2005-02-24 |
EP1663339B1 (en) | 2013-07-31 |
US20070005124A1 (en) | 2007-01-04 |
RU2360646C2 (en) | 2009-07-10 |
WO2005016400A1 (en) | 2005-02-24 |
CN1852744A (en) | 2006-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1663339B1 (en) | Endoluminal prosthesis comprising a therapeutic agent | |
US7229473B2 (en) | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent | |
AU2001261579B2 (en) | Delivery systems for treatment of vascular disease | |
CA2508065C (en) | Antiproliferative drug and delivery device | |
US20020005206A1 (en) | Antiproliferative drug and delivery device | |
JP5385785B2 (en) | Medical stent with a combination of melatonin and paclitaxel | |
US20100268329A1 (en) | Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease | |
JP2005305167A (en) | Medicine/medicine distribution system for prevention and curing of disease of vessel | |
AU2001263113A1 (en) | Drug/drug delivery systems for the prevention and treatment of vascular disease | |
WO2006052521A2 (en) | Medical devices and compositions for treating restenosis | |
WO2003041756A1 (en) | Endoluminal devices coated with latrunculin to prevent ingrowth of cells | |
US8790391B2 (en) | Methods and devices for delivering therapeutic agents to target vessels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060308 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20070416 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1096045 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 624244 Country of ref document: AT Kind code of ref document: T Effective date: 20130815 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602004042920 Country of ref document: DE Effective date: 20130919 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 624244 Country of ref document: AT Kind code of ref document: T Effective date: 20130731 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20130731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130710 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131202 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131101 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1096045 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130831 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130831 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20140502 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130809 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602004042920 Country of ref document: DE Effective date: 20140502 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130731 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130809 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20040809 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20180827 Year of fee payment: 15 Ref country code: DE Payment date: 20180829 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20180828 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004042920 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20190809 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200303 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190809 |